Hello all. I've been lurking on here since back in 2019

New Post Public Reply Private Reply Replies (2) Message Board
Section
1,024
Hello all. I've been lurking on here since back in 2019 when I first invested in Cytodyn. After realizing that the ad popups now have their own ad popups who brought more ad popups to the party, I decided to make an account hoping they back off, but the same gray haired dudes are smirking at me. I know, I'll look at ad blockers. But, since I created an account, why not say hi and let everyone know that there have been tons of us in the background watching this stock for a while now.

Like the dudes in the ads, I normally have a leery look on most stocks, but even through all the craziness of cydy, I've felt optimism. I'm looking forward to a positive result for the CD12 and future trials. From discussions and reading, the science looks on-point.

Anyways, I don't have much to add right now. Maybe a viewpoint from one of the army of outsiders and lurkers.

AF is a fool and everyone seems to realize that now. His hit-piece didn't even dent the stock price, can't even swell a progress or start a scene or two, but no doubt still an easy tool.

Not sure about MDV, never met him, never touched him, not going to touch him now.

The Bruce / Nader thing, maybe going to only discuss lightly. Though I am not a lawyer, I work with patent/copyright lawyers. I asked them about this whole BP/NP thing, which seems to maybe point to technology created while under contract. Specifically, BP's test kits? Maybe technology disputes over patents or something? Many people use patents/tech innovation only for litigation or wonky strong arm techniques. But, we'll see, I'm too far outside to see in. If I find the exact cause of headaches and can run a test for it, I probably can't sue Tylenol and prevent them from selling their product for headaches. So, it's unlikely that being able to verify the cause of a problem being CCL5/RANTES is going to stop a CCR5 inhibitor drug company from continuing to treat the problem.

Stock manipulation on the OTC sucks. We need to get off of this thing. Mulholland needs to get us out of first gear. I'm sure there's a lot to do, so I can't blame him for not succeeding in doing the most important thing for this company's future outside of approvals. We could probably get better funding on Nasdaq, more stability, better control over short-attacks. Hey, Flash, wanna hear a joke?

These ideas of combination therapy are cool, but let's finish the trials we are doing now first. The crew over at Cytodyn have probably written down every possible application, but that doesn't mean there is time nor money until we finish one and get the label.

Nader as CEO. He's a good salesman and knows enough. Could/should he be replaced? Some people on here mention that he doesn't have the deep medical knowledge of the drug. Is that the job of the CEO? Or is it to get the product to market to sell? As CTO and tech lead, I don't expect my CEO crony to know the intricate details of the software, but I do expect him to know enough to sell the hell out of it. It's absurd to require the CEO to be a specialist in the field. Someone with that knowledge would be better suited as CMO. It's funny to entertain the idea, but let's get serious here. You can't split your time like that... that's academia thinking, mock worthy by the real world. The CEO is CEO, CTO is CTO, CMO is CMO, and COO locks up the building for the night.

Future stock price, successes, and failures. If I could successfully forecast these things, I would be a trillionaire. I'm just hanging in there long-term.

FDA for small companies. Unless your job is directly giving them a hand or putting money into their drawers, you probably don't have much sway. You gotta be dirty to hang with that filthy, corrupt bunch. Let's see if the Philippines are more accepting.

I guess that's all for now. Let's see how the results go. Hopefully news soon.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 511

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 472

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 102

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 229

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 561

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 422

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 239

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 480

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 250

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 326

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading

Top 5 Most Recently Viewed Articles

Novagold Merger Faces Class Action Investigation

Updated Category News Views 40

Is Novagold's Merger Really Beneficial? Something smells fishy in the world of precious metals, and no, it’s not the gleam of gold we’re talking about. The latest buzz is about Novagold Resources Inc. (NYSE American: NG) and their merger with Donlin Gold LLC. You know the routine: two companies make googly eyes at each other, and before you know it, there’s a merger...

Continue Reading
Global Hemp Based Food Market Insights and Projections

Updated Category News Views 154

Overview of the Global Hemp-Based Food Market The Global Hemp-Based Food Market is on track for significant growth, expected to rise from USD 1.42 billion to USD 4.87 billion. This represents a strong Compound Annual Growth Rate (CAGR) of 13.12% over the forecast period. The surge in this market can be attributed to increasing health awareness and a growing preference for...

Continue Reading
Carnival's Upcoming Earnings: What Investors Should Know

Updated Category News Views 92

Anticipating Carnival's Earnings Forecast Carnival (NYSE: CCL) is gearing up to unveil its quarterly earnings report soon. Investors are keenly observing the upcoming announcement, which is expected to significantly impact market sentiment. Analysts foresee an earnings per share (EPS) of $0.25, a figure that has generated considerable discussion among stakeholders....

Continue Reading
ModuleMD Revolutionizes Allergy Care at AAAAI 2025 Event

Updated Category News Views 131

ModuleMD Revolutionizes Allergy Care at AAAAI 2025 Event ModuleMD made a significant impact at the recent AAAAI event, showcasing 25 years of dedication to allergy practice solutions. As a leader in this industry, their presentation was not just a display; it was an experience that included innovative product launches, interactive demos, and discussions that captivated...

Continue Reading
Billy Markus Clarifies His Role Amid Bitcoin Speculations

Updated Category News Views 248

Billy Markus, a.k.a. Shibetoshi Nakomoto, has struck back at the endless chatter linking him to Bitcoin—like, c’mon people! This dude is solely about Dogecoin. In a flurry of tongue-in-cheek tweets, he laid bare his status: no ties to Bitcoin or any new crypto projects since his last ride with Doge in 2014. His mantra? If it ain't Dogecoin or his old side gig 'Bells,'...

Continue Reading